Opinion|Videos|March 21, 2025
Latest Advances in the Management of Advanced NSCLC with ALK or ROS1 Mutations
Panelists discuss how the 5-year follow-up data from the CROWN trial support lorlatinib as a frontline treatment for ALK-positive non–small cell lung cancer NSCLC with brain metastasis. For frontline therapy, starting at full dose is preferred, adjusting if needed. Post progression, lorlatinib can be continued or combined with other agents. Biomarker testing for ROS1 is essential, with recent data (TRIDENT-1 trial) favoring lorlatinib for ROS1-positive central nervous system (CNS) involvement. Novel agents like taletrectinib and zidesamtinib from TRUST-I/II and ARROS-1 trials show promise in expanding treatment options for ROS1-positive NSCLC.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on the 5-year follow-up data from the CROWN trial and discuss how these findings inform your first-line treatment approach and in managing ALK-positive NSCLC with brain metastasis. (Solomon BJ, et al. J Clin Oncol. 2024;42(29):3400-3409.)
- Do you prefer starting patients at the full dose with subsequent dose reductions if necessary, or initiating at a lower dose and titrating upward as tolerated?
- For patients receiving lorlatinib in the frontline setting, how do you manage treatment following disease progression?
- Briefly discuss your approach to biomarker testing for ROS1 alterations and how recent data inform your treatment decisions in this space.
- How do the latest data from TRIDENT-1 trial inform your treatment approach for patients with ROS1 alterations and CNS involvement? (Drilon A, et al. NEJM. 2024;390:118-131.)
- Briefly comment on the TRUST-I/II (Perol, M et al. ESMO 2024. Abs 1289P) and ARROS-1 (Besse B, et al. ESMO 2024. Abs 1256MO) trials. Where do you see these novel agents (eg, taletrectinib and zidesamtinib) fitting in the treatment paradigm?
Advertisement
Related to this article
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5